Uniqueness of lung cancer in Southeast Asia

Noronha, Vanita; Budukh, Atul; Chaturvedi, Pankaj; Anne, Srikanth; Punjabi, Anshu; Bhaskar, Maheema; Sahoo, Tarini P.; Menon, Nandini; Shah, Minit; Batra, Ullas; Nathany, Shrinidhi; Kumar, Rajiv; Shetty, Omshree; Ghodke, Trupti Pai; Mahajan, Abhishek; Chakrabarty, Nivedita; Hait, Supriya; Tripathi, Satyendra C.; Chougule, Anuradha; Chandrani, Pratik; Tripathi, Virendra Kumar; Jiwnani, Sabita; Tibdewal, Anil; Maheshwari, Guncha; Kothari, Rushabh; Patil, Vijay M.; Bhat, Rajani Surendar; Khanderia, Mansi; Mahajan, Vandana; Prakash, Ravi; Sharma, Sanjeev; Jabbar, Adnan Abdul; Yadav, Birendra Kumar; Uddin, A.F.M. Kamal; Dutt, Amit; Prabhash, Kumar

doi:10.1016/j.lansea.2024.100430

The Lancet Regional Health - Southeast Asia

2024

DOI: 10.1016/j.lansea.2024.100430

|View full text |Cite

Uniqueness of lung cancer in Southeast Asia

Vanita Noronha,

Atul Budukh,

Pankaj Chaturvedi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial

Noronha,

Menon,

Patil

et al. 2024

Br J Cancer

View full text Add to dashboard Cite

Background Developing effective therapies for cough in lung cancer is an unmet need Neuromodulators like pregabalin may act centrally as cough suppressants. Methods Randomized double-blind placebo-controlled study in patients with locally advanced/metastatic lung cancer and at least 2 weeks of moderate or severe cough. Randomization was 1:1 to pregabalin 300 mg orally daily or matching placebo, both administered for 9 weeks. Primary endpoint was the change in cough severity as measured by the difference in VAS scores. Results Between Jul 2022 and Dec 2023, we enrolled 166 patients: 83 to each arm. Baseline cough severity was grade 2 in 128 (77.1%) and grade 3 in 38 (22.9%) patients; median cough duration was 12 weeks (IQR, 6–20). Systemic cancer-directed therapy was started in 78 (94.0%) and 72 (86.7%) patients in the pregabalin and placebo arms, respectively; P = 0.187. The mean (SD) VAS score (in mm) decreased from 71.58 (14.99) at baseline, to 45.54 (26.60) on day 7, and 22.27 (24.20) by week 9 in the pregabalin arm; and 71.75 (17.58), 46.35 (25.00), and 23.08 (22.42), respectively in the placebo arm; P = 0.877. Conclusion Pregabalin does not significantly decrease cough in patients with lung cancer. Systemic cancer-directed therapy is the most effective antitussive. Clinical trial registration Name of the registry: Clinical Trials Registry India Registration number: CTRI/2020/11/029275 Website: www.ctri.nic.in

show abstract

Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial

Noronha,

Menon,

Patil

et al. 2024

Br J Cancer

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Uniqueness of lung cancer in Southeast Asia

Cited by 1 publication

References 118 publications

Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial

Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial

Contact Info

Product

Resources

About